Early treatment for COVID-19 is available at the Monoclonal Antibody Regional Centers (MARC)
What are Monoclonal Antibodies?
Monoclonal antibodies are proteins made in a lab that help boost the immune system to fight viruses. The monoclonal antibody combination treatment from Regeneron has been authorized for emergency use by the FDA to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg / 88 lbs.) with positive results of direct SARS-CoV-2 (the virus that causes COVID-19) viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. They have been shown in clinical trials to reduce COVID-19-related hospitalization and emergency room visits.
- Medically eligible, symptomatic COVID-19 positive patients whose COVID-19 symptoms have developed within the last 10 days
- Treatment will be provided at no cost to all medically eligible individuals regardless of health insurance or immigration status
- Health Providers
- To refer patients who meet FDA’s EUA criteria, health professionals or their delegated medical staff should call (619) 685-2500 to schedule a patient’s appointment.
- Please provide your patient with the FDA monoclonal antibody EUA Fact Sheet for Patients, Parents and Caregivers (Spanish) to bring to his or her appointment. Patients must wear a mask.
- MARC at Vista Community Clinic
- Treatment site in Vista
MARC at Neighborhood Healthcare
- Treatment site in Escondido
- Family Health Centers
of San Diego
- Treatment sites in Chula Vista and Hillcrest
- Fact Sheets & Other Documents
- Promotional Resources
Questions? Email COVIDtreatment@sdcounty.ca.gov